Nocdurna (Desmopressin)

Desmopressin is a synthetic analogue of vasopressin that selectively stimulates V2 receptors in the kidney collecting ducts. This activation increases cyclic AMP, promoting insertion of aquaporin‑2 channels and enhancing water reabsorption, which reduces urine volume.

The prescribing clinician determines the appropriate dose for each patient. In clinical practice, treatment often starts with a low sublingual dose, such as 0.1 mg taken at bedtime, and may be adjusted based on therapeutic response and serum sodium monitoring.

Desmopressin is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but limited human data. It may be used during pregnancy or lactation only if the potential benefit justifies the potential risk; a healthcare professional should evaluate each case.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Nocdurna is a sublingual tablet, offering rapid absorption and convenient administration compared with nasal sprays or oral melts. While all desmopressin formulations share the same mechanism, the sublingual route may provide more predictable plasma levels and is often preferred for nocturnal dosing.

Nocdurna should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the tablets in a dry, cool environment helps maintain their potency throughout the shelf life.

The tablet is placed under the tongue and allowed to dissolve completely without water. Patients should remain upright for a few minutes after administration and avoid eating or drinking until the tablet has fully dissolved to ensure optimal absorption.

The most critical safety concerns are severe hyponatraemia and water intoxication, which can lead to neurological symptoms such as confusion, seizures, or coma. Regular monitoring of serum sodium and fluid intake is essential to mitigate these risks.

Nocdurna is contraindicated in patients with existing hyponatraemia, uncontrolled hypertension, severe renal impairment, or known hypersensitivity to desmopressin or any tablet excipients. Clinicians should also exercise caution in individuals prone to electrolyte disturbances.